Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2026 01:00 ET | Source: IBA SA

Les 250 meilleurs spécialistes du cancer se réunissent en Belgique pour repousser les frontières de la protonthérapie

IBA réunit les experts les plus renommés en protonthérapie venant des institutions de soins oncologiques les plus prestigieuses. Louvain-la-Neuve, Belgique, le 24 avril 2026 – IBA (Ion Beam...
April 24, 2026 01:00 ET | Source: IBA SA

The top 250 cancer specialists converge in Belgium to push the frontiers of proton therapy

IBA gathers the most knowledgeable proton therapy experts coming from the most prestigious cancer care institutions. Louvain-La-Neuve, Belgium, April 24, 2026 – IBA (Ion Beam Applications S.A.,...
April 22, 2026 19:54 ET | Source: Exicure, Inc.

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Exicure enters co-development agreement with Adbiotech to advance Burixafor (GPC-100) combination therapies across multiple indications.
April 22, 2026 11:00 ET | Source: NETRIS Pharma

NETRIS Pharma: Nature publishes positive pancreatic cancer Phase 1b data for NP137 anti-netrin-1 monoclonal antibody

Positive results from “LAPNET-01,” phase 1b trial of NP137 in patients with pancreatic ductal adenocarcinoma, published in Nature.
April 22, 2026 09:30 ET | Source: LIfT BioSciences

LIfT BioSciences Announces Publication of Review Article in Frontiers in Immunology Highlighting Broad Therapeutic Potential of Neutrophils and IMANs in Cancer

Neutrophils, long considered short-lived immune cells, can be therapeutically targeted when their appropriate subset and functional state are identified for the disease contextLIfT BioSciences’...
April 22, 2026 07:00 ET | Source: EvolveImmune Therapeutics

EvolveImmune Therapeutics Highlights Progress for Lead Asset EVOLVE104 and EVOLVE T Cell Engager Platform in Multiple Presentations at 2026 AACR Annual Meeting

Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to Plan Oral Minisymposium Presentation Demonstrates That EVOLVE T Cell Engagers Drive Greater T Cell Activation, Proliferation and...
April 22, 2026 04:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting

VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through...
April 21, 2026 17:35 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
April 21, 2026 17:30 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with...
April 21, 2026 11:23 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with...